CD274 and nasopharyngeal carcinoma: The KEYNOTE-028 Phase 1b clinical trial of pembrolizumab single agent in PDL1 positive chemo-refractory NPC patients showed a response rate of 26% (7 of 27 patients) (178), which is comparable to the single agent response rate of pembrolizumab in other solid organ tumours (181).